- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
April 14, 2021Robins Kaplan Secures Asylum, Relative Petition for Somali Journalist
-
April 12, 2021Robins Kaplan Executives Recognized by Twin Cities Business
-
April 1, 2021Robert Bennett Named a Midwest Trailblazer
-
April 28, 2021Creating the Audit Clause for Today’s Compliance Review
-
April 29, 2021International Intellectual Property: Challenges of Cross-Border Litigation
-
April 29, 2021Breakthrough Greater Boston Reflections on Resilience Virtual Gala
-
April 13, 2021US Antitrust Regulators Should Foster Climate Collaboration
-
April 2, 2021Prepare For Minn. Privacy Law To Catch Up To Calif., Wash.
-
Spring 2021Fiduciary or Foe? Revisiting Meinhard v. Salmon
-
April 15, 2021Financial Daily Dose 4.15.2021 | Top Story: Big Banks Deliver Huge Q1 Profits, Economic Optimism Despite Ongoing Challenges
-
April 14, 2021Financial Daily Dose 4.14.2021 | Top Story: Crypto Exchange Coinbase Makes Public Debut on Nasdaq
-
April 13, 2021Financial Daily Dose 4.13.2021 | Top Story: Ant Group Agrees to Sweeping Overhaul to Appease Chinese Regulators
IP: India, Generics and the Impact of Novartis’ Failed Gleevec Claims
A recent India Supreme Court decision may have set a higher patentability bar than that of most other countries.
April 23, 2013
India has earned its reputation as “the world’s pharmacy” because it supplies—primarily in the form of generics—much of the affordable medicine needed by countries in the developing world. The country’s $26 billion generic pharmaceutical industry gained the lion’s share of its growth in the period before 2005, when India started offering patent protection to pharmaceuticals. Since then, courts in India have struggled to balance the international trade commitments that prompted the 2005 creation of India’s patent laws with a desire to continue providing wide-spread access to lower cost generic medicines.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Bryan J. Vogel
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.